Chargement en cours...
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
Selumetinib, a highly specific MEK1/2 inhibitor, is approved for children older than 2 years of age with neurofibromatosis 1 (NF1) who have inoperable plexiform neurofibromas. By selectively binding to MEK1/2 proteins, selumetinib can arrest the mitogen-activated protein kinases/extracellular signal...
Enregistré dans:
| Publié dans: | Clin Pharmacokinet |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7935771/ https://ncbi.nlm.nih.gov/pubmed/33354735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00967-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|